These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay. Major TC; Dhamija S; Black N; Liachenko S; Morenko B; Sobocinski G; Okerberg C; Tinholt P; Madore S; Kowala MC J Pharmacol Exp Ther; 2008 Jun; 325(3):723-31. PubMed ID: 18326812 [TBL] [Abstract][Full Text] [Related]
4. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Burnier M; Pruijm M; Wuerzner G Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074 [TBL] [Abstract][Full Text] [Related]
5. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. de la Sierra A J Hum Hypertens; 2009 Aug; 23(8):503-11. PubMed ID: 19148104 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. Pedrinelli R; Dell'Omo G; Nuti M; Menegato A; Balbarini A; Mariani M J Hypertens; 2003 Oct; 21(10):1969-73. PubMed ID: 14508205 [TBL] [Abstract][Full Text] [Related]
7. Nifedipine-sensitive noradrenergic vasoconstriction is enhanced in spontaneously hypertensive rats: the influence of chronic captopril treatment. Paulis L; Lísková S; Pintérová M; Dobesová Z; Kunes J; Zicha J Acta Physiol (Oxf); 2007 Dec; 191(4):255-66. PubMed ID: 17680837 [TBL] [Abstract][Full Text] [Related]
8. Microvascular effects and oedema formation of felodipine in man. Gustafsson D; Länne T; Bjerkhoel P; Johansson P; Lundvall J J Hypertens Suppl; 1989 Sep; 7(4):S161-7; discussion S168. PubMed ID: 2681592 [TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577 [TBL] [Abstract][Full Text] [Related]
15. Orthostatic challenge reveals impaired vascular resistance control, but normal venous pooling and capillary filtration in familial dysautonomia. Brown CM; Stemper B; Welsch G; Brys M; Axelrod FB; Hilz MJ Clin Sci (Lond); 2003 Feb; 104(2):163-9. PubMed ID: 12546638 [TBL] [Abstract][Full Text] [Related]
16. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs. Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla. Aota Y; Morimoto S; Sakuma T; Morita T; Jo F; Takahashi N; Maehara M; Ikeda K; Sawada S; Iwasaka T Hypertens Res; 2009 Aug; 32(8):700-5. PubMed ID: 19521420 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacological evaluation of calcium antagonists and other drugs modifying myogenic tone in essential hypertension. Reid JL; Donnelly R; Meredith PA; Elliott HL J Hypertens Suppl; 1989 Sep; 7(4):S169-71. PubMed ID: 2681593 [TBL] [Abstract][Full Text] [Related]
19. Effects of calcium channel blockers on hyaluronidase-induced capillary vascular permeability. Halici Z; Suleyman H; Cadirci E Arch Pharm Res; 2008 Jul; 31(7):891-9. PubMed ID: 18704332 [TBL] [Abstract][Full Text] [Related]